Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 49, Issue 2, 2007, Pages 133-138

  Rodrigues, Patricia C ^a   Oliveira, Sátiro N ^a   Viana, Marcos B ^b   Matsuda, Eduardo I ^a   Nowill, Alexandre E ^c   Brandalise, Silvia R ^a,c   Yunes, José A ^a  

^a CENTRO INFANTIL BOLDRINI   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Childhood AML; inv(16); Prognosis; RQ PCR; t(8; 21); WT1

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CHILD; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CYTOGENETICS; DNA SYNTHESIS; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WT1 GENE;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAZIL; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, WILMS TUMOR; HUMANS; INFANT; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; WT1 PROTEINS;

EID: 34447279071     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20953     Document Type: Article

References (40)

1. Haber DA, Buckler AJ. A novel tumor suppressor gene inactivated in Wilms' tumor. New Biol 1992;4:97-106.
2. Call KM, Glasser T, Ito CY, et al. Isolation and characterization of a zinc-finger polypeptide gene at the human chromosome 11 Wilms' tumor Locus. Cell 1990;60:509-520.
3. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
4. Baird PN, Simmons PJ. Expression of the Wilms'tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-320.
5. Maurer U, Brieger J, Weidmann E, et al. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in course of differentiation in vitro. Exp Hematol 1997;25: 945-950.
6. Menssen HD, Renkl HJ, Entezami M, et al. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997;89: 3486-3487.
7. Maurer U, Weidmann E, Karakas T, et al. Wilms tumor gene (Wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997;90:4230-4232.
8. Ellisen LW, Carlesso N, Cheng T, et al. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001;20: 1897-1909.
9. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of the Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-1067.
10. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
11. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3079.
12. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89: 1405-1412.
13. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267-2278.
14. Spinsanti P, de Grazia U, Faggioni A, et al. Wilms' tumor gene expression by normal and malignant human B lymphocytes. Leuk Lymphoma 2000;38:611-619.
15. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393-399.
16. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99:3272-3279.
17. Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988-1995.
18. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90: 1217-1225.
19. Garg M, Moore H, Tobal K, et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003;123:49-59.
20. Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-933.
21. Schmid D, Heinze G, Linnerth B. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643.
22. Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005;19:1416-1423.
23. Gaiger A, Linnerth B, Mann G, et al. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur J Haematol 1999;63:86-93.
24. Niegemann E, Wehner S, Kornhuber B, et al. WT1 gene expression in childhood leukemias. Acta Haematol 1999;102:72-76.
25. Im HJ, Kong G, Lee H. Expression of Wilms tumor gene (WT1) in children with acute leukemia. Pediatr Hematol Oncol 1999;16: 109-118.
26. Kletzel M, Olzewski M, Huang W, et al. Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia. Pediatr Dev Pathol 2002;5:269-275.
27. Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002;16:1381-1389.
28. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990;75:1932-1940.
29. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of the acute myeloid leukemia. A report of the French-American-British co-operative group. Br J Haematol 1976;33:451-458.
30. Viana MB, Cunha KCCMS, Ramos G, et al. Acute myeloid leukemia in childhood: Fifteen-year experience in a single institution. J Pediatr (Rio J) 2003;79:489-496.
31. Douer D, Preston-Martin S, Chang E, et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;87:308-313.
32. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;88:377.
33. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
34. Watzinger F, Lion T. Multiplex PCR for quality control of template RNA/cDNA in RT-PCR assays. Leukemia 1998;11: 1984-1986.
35. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999;13: 1901-1928.
36. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - A Europe against cancer program. Leukemia 2003;17:2474-2486.
37. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-2121.
38. Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol 2004;31:185-197.
39. Yanada M, Terakura S, Yokozawa T, et al. Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004;45:1803-1808.
40. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104:630-639.